Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation.

Name: Αlpha¹ Rigor Record — Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation.
Item: Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation.
Rating: 96
Author: Αlpha¹

Verma A, Birnie DH, Jiang C, Heidbüchel H, Hindricks G, Kirchhof P, Healey JS, Wang Y, Dagres N, Deyell MW, Sanders P, Pathak RK, Koopman P, Nuyens D, Novak P, Amit G, Dussault C, Makanjee B, Quinn FR, Jolly U, Iden L, Kuniss M, Sharma M, Ha A, Essebag V, Champagne J, Hill MD, Smith EE, Wells GA, OCEAN Investigators

Paper source

Read full text

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.75★ (Weak), 0 critical, 2 high issues for “Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

CitationsCitations & links (capped) ×5−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Citations & links are capped at −1★ combined, however many are flagged.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 10 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
No data or code availability links were detected to verify.

Problems surfaced4 types

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported randomized clinical trial with rigorous design, clear ethics approvals, and appropriate statistical methods. The main weakness is the vague data availability statement, which does not specify the access mechanism or repository. Minor reporting gaps include lack of explicit CONSORT adherence and a typo in the author affiliations.

Both reviewers independently scored all eight dimensions and agreed on all statuses; no divergence required reconciliation. The statistics component recomputed only 3 tests (those with test statistics/df or effect+CI); the remaining analyses were not machine-verified and should not be assumed correct. The citation check flagged 5 references as not found in registries, which may indicate fabrication or incorrect DOIs.

4 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 3 tests: 3 consistent, 0 inconsistent; 3 via agent-written checks.

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites prior studies and guidelines, acknowledges that current recommendations are based on small nonrandomized studies, and states the trial's purpose. The rationale linking the premise to the objective is explicit. Limitations of prior research are addressed by noting the lack of randomized data.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with prior work cited and a logical rationale for the trial.

Evidence

direct quote[Introduction, paragraph 1]

“These recommendations are based on evidence from small, nonrandomized studies.”